Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer Journal Article
| Authors: | Lynce, F.; Robson, M. |
| Article Title: | Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer |
| Abstract: | The use of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of patients with germline BRCA mutations (gBRCAm) and breast cancer, both in the early and advanced settings, is a success of genomically-directed treatment. These agents have been shown to be associated with longer progression-free survival when compared to standard chemotherapy, with an acceptable toxicity profile. A recent randomized trial demonstrated improved survival with the use of olaparib for 2 years compared to placebo in patients with early-stage high risk gBRCAm associated breast cancer. Ongoing research efforts are focused on identifying patients beyond those with BRCA1/2 or PALB2 mutations who may benefit from PARP inhibitors, exploring the overlapping mechanisms of resistance between platinum and PARP inhibitors and developing agents with less toxicity that will allow combinational strategies. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2023. |
| Keywords: | cancer surgery; gene mutation; genetics; doxorubicin; solid tumor; capecitabine; gemcitabine; paclitaxel; cancer radiotherapy; clinical practice; ovarian neoplasms; carboplatin; breast cancer; cyclophosphamide; autologous stem cell transplantation; breast neoplasms; brca1 protein; brca2 protein; tumor suppressor gene; breast tumor; ovary tumor; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; neoadjuvant chemotherapy; metastatic breast cancer; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase; brca1 protein, human; radiosensitization; eribulin; olaparib; poly(adp-ribose) polymerases; veliparib; brca2 protein, human; niraparib; humans; human; female; parp inhibitors; pembrolizumab; durvalumab; atezolizumab; poly(adp-ribose) polymerase inhibitors; vinorelbine tartrate; brca1/2 mutations; talazoparib; homologous recombination deficiency (hrd); hormone receptor-positive, her2-negative breast cancer |
| Journal Title: | Cancer Treatment and Research |
| Volume: | 186 |
| ISSN: | 0927-3042 |
| Publisher: | Springer |
| Date Published: | 2023-01-01 |
| Start Page: | 91 |
| End Page: | 102 |
| Language: | English |
| DOI: | 10.1007/978-3-031-30065-3_6 |
| PROVIDER: | scopus |
| PUBMED: | 37978132 |
| DOI/URL: | |
| Notes: | Chapter 6 in "Targeting the DNA Damage Response for Cancer Therapy" (ISBN: 978-3-031-30064-6) -- Source: Scopus |
